查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867555

治疗性RNAi－全球市场占有率和排名、总收入和需求预测（2025-2031年）

RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球治疗性 RNAi 市场预计在 2024 年达到 22.78 亿美元，预计到 2031 年将达到 131.25 亿美元，2025 年至 2031 年的复合年增长率为 27.5%。

RNA干扰（RNAi）疗法是一种先进的分子医学技术，它利用双链RNA分子（例如siRNA和shRNA）选择性地沉默标靶基因表现。这可以抑制致病基因的转录和翻译，从而实现对多种遗传性疾病、罕见疾病、癌症和病毒感染疾病的精准治疗。此技术可在不改变DNA序列的情况下，在RNA层面进行可逆、高度特异性且低毒性的干预。自从首个RNAi疗法核准，该领域已迅速从研究阶段迈向商业化阶段，并在肝臟、神经系统和肿瘤治疗等领域展现出巨大的潜力。随着递送系统的突破和临床研发管线的不断扩展，RNAi疗法正成为精准医疗和基因治疗产业的重要策略支柱。

由于多种因素，RNAi疗法的全球推广正在加速。基因组学和RNA生物学的进步使得精准药物设计成为可能，而新型递送技术，例如脂质奈米颗粒（LNP）和GalNAc偶联物，显着提高了药物对肝臟和其他组织的靶向效率。此外，多个国家加快监管审批的政策缩短了从研发到商业化的时间。大型製药和生技公司正积极透过併购和合作来拓展临床适应症范围，从而促进RNAi疗法在罕见疾病、代谢性疾病和心血管疾病领域的市场应用。儘管RNAi疗法具有革命性的潜力，但仍面临着技术、商业性和监管方面的障碍。递送效率和组织特异性仍然是主要瓶颈，尤其是在中枢神经系统和固态肿瘤。此外，RNAi分子可能诱发特异性免疫反应和脱靶效应，进而影响安全性和有效性。从商业角度来看，高昂的生产成本和严格的品管标准限制了生产规模和利润率。智慧财产权壁垒以及核心专利集中在少数几家主要企业手中，进一步增加了新进入者的技术和法律门槛。下游市场需求日益分散和多样化。缺乏有效治疗方法的罕见疾病治疗高度依赖RNAi解决方案，并可能带来早期商业突破。同时，心血管和代谢性疾病患者群体庞大，蕴藏长期成长潜力。在肿瘤学和免疫疗法领域，RNAi正在与查核点抑制剂、CAR-T疗法和其他治疗方法形成新的合併治疗方案。随着个人化医疗和伴随诊断的兴起，RNAi疗法将更深入地融入临床路径，实现精准分层和标靶干预，从而推动对更高效率、安全性和可控性的需求。

本报告旨在对全球治疗性 RNAi 市场进行全面分析，重点关注总收入、企业市场占有率和主要企业的排名，并按地区/国家、类型和应用进行分析。

本报告以销售收入为基准年（2024 年），对治疗性 RNAi 市场规模、估算和预测进行了呈现，并包含了 2020 年至 2031 年的历史数据和预测数据。报告运用定量和定性分析，帮助读者制定治疗性 RNAi 的业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Arrowhead
  • Silence Therapeutics
  • Benitec Biopharma
  • Phio Pharmaceuticals
  • RXi Pharmaceuticals
  • Arrakis Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

按类型分類的细分市场

  • siRNA
  • miRNA
  • shRNA

应用领域

  • 癌症
  • 心血管系统
  • B型肝炎病毒
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for RNAi for Therapeutic was estimated to be worth US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.

RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.

The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

Market Segmentation

By Company

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Arrowhead
  • Silence Therapeutics
  • Benitec Biopharma
  • Phio Pharmaceuticals
  • RXi Pharmaceuticals
  • Arrakis Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

Segment by Type

  • siRNA
  • miRNA
  • shRNA

Segment by Application

  • Cancer
  • Cardiovascular
  • HBV
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 RNAi for Therapeutic Product Introduction
  • 1.2 Global RNAi for Therapeutic Market Size Forecast (2020-2031)
  • 1.3 RNAi for Therapeutic Market Trends & Drivers
    • 1.3.1 RNAi for Therapeutic Industry Trends
    • 1.3.2 RNAi for Therapeutic Market Drivers & Opportunity
    • 1.3.3 RNAi for Therapeutic Market Challenges
    • 1.3.4 RNAi for Therapeutic Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global RNAi for Therapeutic Players Revenue Ranking (2024)
  • 2.2 Global RNAi for Therapeutic Revenue by Company (2020-2025)
  • 2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies RNAi for Therapeutic Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic
  • 2.6 RNAi for Therapeutic Market Competitive Analysis
    • 2.6.1 RNAi for Therapeutic Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 siRNA
    • 3.1.2 miRNA
    • 3.1.3 shRNA
  • 3.2 Global RNAi for Therapeutic Sales Value by Type
    • 3.2.1 Global RNAi for Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2020-2031)
    • 3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cancer
    • 4.1.2 Cardiovascular
    • 4.1.3 HBV
    • 4.1.4 Others
  • 4.2 Global RNAi for Therapeutic Sales Value by Application
    • 4.2.1 Global RNAi for Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2020-2031)
    • 4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global RNAi for Therapeutic Sales Value by Region
    • 5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global RNAi for Therapeutic Sales Value by Region (2020-2025)
    • 5.1.3 Global RNAi for Therapeutic Sales Value by Region (2026-2031)
    • 5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America RNAi for Therapeutic Sales Value, 2020-2031
    • 5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe RNAi for Therapeutic Sales Value, 2020-2031
    • 5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2020-2031
    • 5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America RNAi for Therapeutic Sales Value, 2020-2031
    • 5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions RNAi for Therapeutic Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States RNAi for Therapeutic Sales Value, 2020-2031
    • 6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe RNAi for Therapeutic Sales Value, 2020-2031
    • 6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China RNAi for Therapeutic Sales Value, 2020-2031
    • 6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan RNAi for Therapeutic Sales Value, 2020-2031
    • 6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea RNAi for Therapeutic Sales Value, 2020-2031
    • 6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2020-2031
    • 6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India RNAi for Therapeutic Sales Value, 2020-2031
    • 6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Alnylam Pharmaceuticals
    • 7.1.1 Alnylam Pharmaceuticals Profile
    • 7.1.2 Alnylam Pharmaceuticals Main Business
    • 7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
    • 7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Alnylam Pharmaceuticals Recent Developments
  • 7.2 Arrowhead Pharmaceuticals
    • 7.2.1 Arrowhead Pharmaceuticals Profile
    • 7.2.2 Arrowhead Pharmaceuticals Main Business
    • 7.2.3 Arrowhead Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
    • 7.2.4 Arrowhead Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Arrowhead Pharmaceuticals Recent Developments
  • 7.3 Arrowhead
    • 7.3.1 Arrowhead Profile
    • 7.3.2 Arrowhead Main Business
    • 7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions
    • 7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Arrowhead Recent Developments
  • 7.4 Silence Therapeutics
    • 7.4.1 Silence Therapeutics Profile
    • 7.4.2 Silence Therapeutics Main Business
    • 7.4.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
    • 7.4.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Silence Therapeutics Recent Developments
  • 7.5 Benitec Biopharma
    • 7.5.1 Benitec Biopharma Profile
    • 7.5.2 Benitec Biopharma Main Business
    • 7.5.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
    • 7.5.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Benitec Biopharma Recent Developments
  • 7.6 Phio Pharmaceuticals
    • 7.6.1 Phio Pharmaceuticals Profile
    • 7.6.2 Phio Pharmaceuticals Main Business
    • 7.6.3 Phio Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
    • 7.6.4 Phio Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Phio Pharmaceuticals Recent Developments
  • 7.7 RXi Pharmaceuticals
    • 7.7.1 RXi Pharmaceuticals Profile
    • 7.7.2 RXi Pharmaceuticals Main Business
    • 7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
    • 7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.7.5 RXi Pharmaceuticals Recent Developments
  • 7.8 Arrakis Therapeutics
    • 7.8.1 Arrakis Therapeutics Profile
    • 7.8.2 Arrakis Therapeutics Main Business
    • 7.8.3 Arrakis Therapeutics RNAi for Therapeutic Products, Services and Solutions
    • 7.8.4 Arrakis Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Arrakis Therapeutics Recent Developments
  • 7.9 Benitec Biopharma
    • 7.9.1 Benitec Biopharma Profile
    • 7.9.2 Benitec Biopharma Main Business
    • 7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
    • 7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Benitec Biopharma Recent Developments
  • 7.10 miRagen Therapeutics
    • 7.10.1 miRagen Therapeutics Profile
    • 7.10.2 miRagen Therapeutics Main Business
    • 7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
    • 7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.10.5 miRagen Therapeutics Recent Developments
  • 7.11 Sylentis
    • 7.11.1 Sylentis Profile
    • 7.11.2 Sylentis Main Business
    • 7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions
    • 7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Sylentis Recent Developments
  • 7.12 Gradalis
    • 7.12.1 Gradalis Profile
    • 7.12.2 Gradalis Main Business
    • 7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions
    • 7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Gradalis Recent Developments
  • 7.13 Sirnaomics
    • 7.13.1 Sirnaomics Profile
    • 7.13.2 Sirnaomics Main Business
    • 7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions
    • 7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Sirnaomics Recent Developments
  • 7.14 Silenseed
    • 7.14.1 Silenseed Profile
    • 7.14.2 Silenseed Main Business
    • 7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions
    • 7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Silenseed Recent Developments

8 Industry Chain Analysis

  • 8.1 RNAi for Therapeutic Industrial Chain
  • 8.2 RNAi for Therapeutic Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 RNAi for Therapeutic Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 RNAi for Therapeutic Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. RNAi for Therapeutic Market Trends
  • Table 2. RNAi for Therapeutic Market Drivers & Opportunity
  • Table 3. RNAi for Therapeutic Market Challenges
  • Table 4. RNAi for Therapeutic Market Restraints
  • Table 5. Global RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies RNAi for Therapeutic Product Type
  • Table 9. Key Companies Time to Begin Mass Production of RNAi for Therapeutic
  • Table 10. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global RNAi for Therapeutic Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global RNAi for Therapeutic Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global RNAi for Therapeutic Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global RNAi for Therapeutic Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global RNAi for Therapeutic Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global RNAi for Therapeutic Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global RNAi for Therapeutic Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global RNAi for Therapeutic Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global RNAi for Therapeutic Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global RNAi for Therapeutic Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global RNAi for Therapeutic Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global RNAi for Therapeutic Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global RNAi for Therapeutic Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global RNAi for Therapeutic Sales Value by Region (2020-2025) & (%)
  • Table 27. Global RNAi for Therapeutic Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions RNAi for Therapeutic Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions RNAi for Therapeutic Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Alnylam Pharmaceuticals Basic Information List
  • Table 32. Alnylam Pharmaceuticals Description and Business Overview
  • Table 33. Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in RNAi for Therapeutic Business of Alnylam Pharmaceuticals (2020-2025)
  • Table 35. Alnylam Pharmaceuticals Recent Developments
  • Table 36. Arrowhead Pharmaceuticals Basic Information List
  • Table 37. Arrowhead Pharmaceuticals Description and Business Overview
  • Table 38. Arrowhead Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead Pharmaceuticals (2020-2025)
  • Table 40. Arrowhead Pharmaceuticals Recent Developments
  • Table 41. Arrowhead Basic Information List
  • Table 42. Arrowhead Description and Business Overview
  • Table 43. Arrowhead RNAi for Therapeutic Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead (2020-2025)
  • Table 45. Arrowhead Recent Developments
  • Table 46. Silence Therapeutics Basic Information List
  • Table 47. Silence Therapeutics Description and Business Overview
  • Table 48. Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in RNAi for Therapeutic Business of Silence Therapeutics (2020-2025)
  • Table 50. Silence Therapeutics Recent Developments
  • Table 51. Benitec Biopharma Basic Information List
  • Table 52. Benitec Biopharma Description and Business Overview
  • Table 53. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2020-2025)
  • Table 55. Benitec Biopharma Recent Developments
  • Table 56. Phio Pharmaceuticals Basic Information List
  • Table 57. Phio Pharmaceuticals Description and Business Overview
  • Table 58. Phio Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in RNAi for Therapeutic Business of Phio Pharmaceuticals (2020-2025)
  • Table 60. Phio Pharmaceuticals Recent Developments
  • Table 61. RXi Pharmaceuticals Basic Information List
  • Table 62. RXi Pharmaceuticals Description and Business Overview
  • Table 63. RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in RNAi for Therapeutic Business of RXi Pharmaceuticals (2020-2025)
  • Table 65. RXi Pharmaceuticals Recent Developments
  • Table 66. Arrakis Therapeutics Basic Information List
  • Table 67. Arrakis Therapeutics Description and Business Overview
  • Table 68. Arrakis Therapeutics RNAi for Therapeutic Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrakis Therapeutics (2020-2025)
  • Table 70. Arrakis Therapeutics Recent Developments
  • Table 71. Benitec Biopharma Basic Information List
  • Table 72. Benitec Biopharma Description and Business Overview
  • Table 73. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2020-2025)
  • Table 75. Benitec Biopharma Recent Developments
  • Table 76. miRagen Therapeutics Basic Information List
  • Table 77. miRagen Therapeutics Description and Business Overview
  • Table 78. miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in RNAi for Therapeutic Business of miRagen Therapeutics (2020-2025)
  • Table 80. miRagen Therapeutics Recent Developments
  • Table 81. Sylentis Basic Information List
  • Table 82. Sylentis Description and Business Overview
  • Table 83. Sylentis RNAi for Therapeutic Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in RNAi for Therapeutic Business of Sylentis (2020-2025)
  • Table 85. Sylentis Recent Developments
  • Table 86. Gradalis Basic Information List
  • Table 87. Gradalis Description and Business Overview
  • Table 88. Gradalis RNAi for Therapeutic Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in RNAi for Therapeutic Business of Gradalis (2020-2025)
  • Table 90. Gradalis Recent Developments
  • Table 91. Sirnaomics Basic Information List
  • Table 92. Sirnaomics Description and Business Overview
  • Table 93. Sirnaomics RNAi for Therapeutic Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in RNAi for Therapeutic Business of Sirnaomics (2020-2025)
  • Table 95. Sirnaomics Recent Developments
  • Table 96. Silenseed Basic Information List
  • Table 97. Silenseed Description and Business Overview
  • Table 98. Silenseed RNAi for Therapeutic Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in RNAi for Therapeutic Business of Silenseed (2020-2025)
  • Table 100. Silenseed Recent Developments
  • Table 101. Key Raw Materials Lists
  • Table 102. Raw Materials Key Suppliers Lists
  • Table 103. RNAi for Therapeutic Downstream Customers
  • Table 104. RNAi for Therapeutic Distributors List
  • Table 105. Research Programs/Design for This Report
  • Table 106. Key Data Information from Secondary Sources
  • Table 107. Key Data Information from Primary Sources

List of Figures

  • Figure 1. RNAi for Therapeutic Product Picture
  • Figure 2. Global RNAi for Therapeutic Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global RNAi for Therapeutic Sales Value (2020-2031) & (US$ Million)
  • Figure 4. RNAi for Therapeutic Report Years Considered
  • Figure 5. Global RNAi for Therapeutic Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by RNAi for Therapeutic Revenue in 2024
  • Figure 7. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. siRNA Picture
  • Figure 9. miRNA Picture
  • Figure 10. shRNA Picture
  • Figure 11. Global RNAi for Therapeutic Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global RNAi for Therapeutic Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Cancer
  • Figure 14. Product Picture of Cardiovascular
  • Figure 15. Product Picture of HBV
  • Figure 16. Product Picture of Others
  • Figure 17. Global RNAi for Therapeutic Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global RNAi for Therapeutic Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America RNAi for Therapeutic Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific RNAi for Therapeutic Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions RNAi for Therapeutic Sales Value (%), (2020-2031)
  • Figure 30. United States RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031
  • Figure 51. RNAi for Therapeutic Industrial Chain
  • Figure 52. RNAi for Therapeutic Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed